Cargando…

Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia

Regulatory agencies have sought to speed up the review of new cancer medicines and reduce delays in approval between countries. We examined trends in regulatory review times and association with clinical benefit for new cancer medicines in six jurisdictions: United States (Food and Drug Administrati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hwang, Thomas J., Kesselheim, Aaron S., Tibau, Ariadna, Lee, ChangWon C., Vokinger, Kerstin N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2022
Materias:	ORIGINAL CONTRIBUTIONS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509186/ https://www.ncbi.nlm.nih.gov/pubmed/35731996 http://dx.doi.org/10.1200/OP.21.00909

Ejemplares similares

Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study
por: Hwang, Thomas J, et al.
Publicado: (2020)

Clinical benefit of cancer drugs approved in Switzerland 2010–2019
por: Adam, Roman, et al.
Publicado: (2022)

Comparison of the new Japanese legislation for expedited approval of regenerative medicine products with the existing systems in the USA and European Union
por: Jokura, Yoji, et al.
Publicado: (2017)

Therapeutic Value of Drugs Granted Accelerated Approval or Conditional Marketing Authorization in the US and Europe From 2007 to 2021
por: Vokinger, Kerstin N., et al.
Publicado: (2022)

The Potential Benefit of Expedited Development and Approval Programs in Precision Medicine
por: Kantor, Ariel, et al.
Publicado: (2021)

Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study
por: Kesselheim, Aaron S, et al.
Publicado: (2015)

Predictors of orphan drug approval in the European Union
por: Heemstra, Harald E., et al.
Publicado: (2008)

Comparison of rates of safety issues and reporting of trial outcomes for medical devices approved in the European Union and United States: cohort study
por: Hwang, Thomas J, et al.
Publicado: (2016)

Regulatory approval for autologous human cells and tissue products in the United States, the European Union, and Japan
por: Yano, Kazuo, et al.
Publicado: (2014)

Application of orphan drug designation to cancer treatments (2008–2017): a comprehensive and comparative analysis of the USA and EU
por: Vokinger, Kerstin Noëlle, et al.
Publicado: (2019)

Fragility of randomized trials supporting cancer drug approvals stratified by approval pathway and review designations
por: Wilson, Brooke E., et al.
Publicado: (2021)

Imported Rabies, European Union and Switzerland, 2001–2010
por: Johnson, Nicholas, et al.
Publicado: (2011)

Safety related label changes for new drugs after approval in the US through expedited regulatory pathways: retrospective cohort study
por: Mostaghim, Sana R, et al.
Publicado: (2017)

Approval and Certification of Ophthalmic AI Devices in the European Union
por: Grzybowski, Andrzej, et al.
Publicado: (2023)

Patients’ access to drugs with rebates in Switzerland – Empirical analysis and policy implications for drug pricing in Europe
por: Carl, David L, et al.
Publicado: (2021)

Mitigating bias in machine learning for medicine
por: Vokinger, Kerstin N., et al.
Publicado: (2021)

Expedited approval system for regenerative medicine products – Is it unusual?
por: Yano, Kazuo, et al.
Publicado: (2016)

Expedited regulatory product approval in the time of COVID-19
por: Novack, Gary D.
Publicado: (2022)

Characteristics of Postmarketing Studies for Vaccines Approved by the US Food and Drug Administration, 2006-2020
por: Moneer, Osman, et al.
Publicado: (2021)

Single-arm trials supporting the approval of anticancer medicinal products in the European Union: contextualization of trial results and observed clinical benefit
por: Mulder, J., et al.
Publicado: (2023)

Comparison of Uptake and Prices of Biosimilars in the US, Germany, and Switzerland
por: Carl, David L., et al.
Publicado: (2022)

Cell-based medicinal products approved in the European Union: current evidence and perspectives
por: Bellino, Stefania, et al.
Publicado: (2023)

FDA expedited approval and implications for rational formulary and health plan design
por: Ferries, Erin A, et al.
Publicado: (2021)

Application of national pollutant inventories for monitoring trends on dioxin emissions from stationary industrial sources in Australia, Canada and European Union
por: Salian, Khushbu, et al.
Publicado: (2019)

Navigating the maze of requirements for obtaining approval of non-interventional studies (NIS) in the European Union
por: Ramirez, Isabelle
Publicado: (2015)

Engineered Microorganisms for the Production of Food Additives Approved by the European Union—A Systematic Analysis
por: Kallscheuer, Nicolai
Publicado: (2018)

Alcohol consumption: context and association with mortality in Switzerland
por: Suter, Flurina, et al.
Publicado: (2022)

Post‐Marketing Requirements for Cancer Drugs Approved by the European Medicines Agency, 2004–2014
por: Cherla, Avi, et al.
Publicado: (2022)

Comprehensive mapping of national school food policies across the European Union plus Norway and Switzerland
por: Storcksdieck genannt Bonsmann, S
Publicado: (2014)

Therapeutic Value Assessments of Novel Medicines in the US and Europe, 2018-2019
por: Vokinger, Kerstin N., et al.
Publicado: (2022)

Locally Acquired Leptospirosis in Expedition Racer, Manitoba, Canada
por: Kassim, Sameer S., et al.
Publicado: (2018)

Regulatory Pathways Supporting Expedited Drug Development and Approval in ICH Member Countries
por: Franco, Pedro, et al.
Publicado: (2022)

How Does Medical Device Regulation Perform in the United States and the European Union? A Systematic Review
por: Kramer, Daniel B., et al.
Publicado: (2012)

Delayed Union of Fractures, with Report of Three Cases
por: Anderson, J. C.
Publicado: (1903)

Expedited approval of cancer drugs without randomized controlled trials: Too good to be true?
por: Shepshelovich, Daniel, et al.
Publicado: (2018)

Use of Expedited Regulatory Programs and Clinical Development Times for FDA-Approved Novel Therapeutics
por: Wong, Alissa K., et al.
Publicado: (2023)

COVID-19 treatments approved in the European Union and clinical recommendations for the management of non-hospitalized and hospitalized patients
por: Bellino, Stefania
Publicado: (2022)

Epidemiology and contemporary risk profile of traumatic spinal cord injury in Switzerland
por: Chamberlain, Jonviea D., et al.
Publicado: (2015)

The South African Medicines Control Council: Comparison of Its Registration Process With Australia, Canada, Singapore, and Switzerland
por: Keyter, Andrea, et al.
Publicado: (2019)

Comparison of BRICS-TM Countries' Biosimilar Regulatory Frameworks With Australia, Canada and Switzerland: Benchmarking Best Practices
por: Rahalkar, Hasumati, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_khv6thjlts0ajfh90ehvrs302e